Searched for
MULTINATIONAL PHARMA FIRMS
Healthium Medtech CEO Anish Bafna steps down, moves to non-executive chairman roleHealthium Medtech's CEO Anish Bafna is transitioning to non-executive chairman as KKR-owned company seeks a new chief within a month. Bafna...- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Demand for senior technology leaders in India is bucking a slowdown in broader tech hiringAs per experts, many MNCs are considering shifting global tech positions to India, mostly to their GCCs. Ratna Gupta, senior partner, ABC C...
- Cipla, Natco Pharma, Hetero Labs among Indian firms chosen to supply key generic drugs in ChinaIndian firms Hetero Labs Limited, Cipla Ltd, Annora Pharma Private Limited and Natco Pharma won the bids conducted by the Chinese health mi...
- Biocon signs up with external law firm to review governance process at vendor firms"The company already has a strong code of conduct and an anti-bribery and anti-corruption clause in its contracts with all its vendors. The...
- Dilip Shanghvi, second-wealthiest Indian, is the poorest pharma CEOShanghvi’s salary for 2013-14 was Rs 2.73 crore, according to data sifted by ET from filings of leading listed drug companies.
- How does the Sun Pharma-Ranbaxy deal change the game for the other players in the Indian pharma market?The combined market share of Sun Pharma (5.4% at present) and Ranbaxy (3.8%) will be 9.2%; much higher than that of the current No. 1 playe...
- FDI in pharma doubled during April to DecemberThe government had cleared a Rs 5,168 crore proposal of US-based pharma firm Mylan Inc's to acquire Indian generic drugs company Agila Spec...
- Dose of bitter pills, few booster injections for pharma sectorThe pharma sector, estimated to be around Rs 1.5 lakh cr, recorded single digit growth for the first time in many years on account of deepe...
- FDI in pharma sector doubled during April-AugustFaced with rush of multinationals to acquire Indian pharma firms, the Commerce and Industry Ministry is proposing to tighten the FDI policy...
- Is FDI in pharma giving desired results, wonders DIPPThe DIPP said current norms must lay down the foundation of what should be the nature of Indian drug companies in the long term.
- Govt to finalise FDI policy in pharma before FIPB meetThe government is likely to finalise FDI policy with regard to existing drug companies ahead of the FIPB meeting on July 5.
- DIPP wants relook of FDI policy in pharma at PM levelWith no let up in multinationals seeking nod to acquire stake in Indian pharma firms despite government putting norms to check it.
- Big pharma firms face credible local competition; may ditch their fixation with patentsDespite Novartis setback on cancer drug patent plea, multinational pharma firms cannot ignore emerging markets such as India and China.
- GSK Pharma: Investors must be careful of the competitive threats it faces in IndiaWhile the company's performance in the June quarter was strong sequentially, it will be interesting to see GSK's strategies to overcome the...
- South Africa-based Adcock Ingram buys Cosme Farma for Rs 480 croreSouth Africa-based drug maker Adcock Ingram has quietly acquired privately-held Cosme Farma for Rs 480 crore, a 13 times premium over Cosme...
- FDI curbs in pharma could deter MNCs: Kewal Handa, Pfizer India MDIndia's attempts to check foreign investment in pharma and expand drug pricing control could force multinationals to exit the country.
- Govt not to allow trials for drugs developed outside IndiaThe health ministry will put on hold its plans to grant permissions to multinational pharma firms for conducting phase I clinical trials of...
- All are invited to this Rs 27,000-cr pharma partyThe domestic pharma sector’s better-than-global-average growth is creating new streams of allied business in this Rs 27,000-crore industry.
- New excise regime may take sheen off outsourcing dealsThe new excise duty regime for pharmaceuticals is expected to trigger a shift in the outsourcing business, touted as a big opportunity for ...
Load More
